Gut-targeted dietary FIBER interventions in type 2 and gestational diabetes: Mechanisms and clinical evidence

Introduction

The International Diabetes Federation (IDF) estimates that 537 million adults globally lived with diabetes in 2023, a figure projected to escalate to 783 million by 2045. Type 2 diabetes mellitus (T2DM) represents over 90% of these cases, primarily driven by rising obesity rates and sedentary lifestyles. Simultaneously, gestational diabetes mellitus (GDM) affects up to 14% of pregnancies worldwide, presenting acute risks such as preeclampsia and macrosomia, while significantly increasing the long-term risk of T2DM for both mother and offspring. While pharmacological treatments are effective, dietary fiber has emerged as a critical nonpharmacological tool for modulating glycemic responses through its resistance to smallintestinal digestion and subsequent colonic fermentation into bioactive metabolites. Despite the shared feature of hyperglycemia, the metabolic mechanisms of dietary fiber differ and overlap significantly between T2DM and GDM. In both conditions, fiber -derived short-chain fatty acids (SCFAs) enhance insulin sensitivity and stimulate incretin hormones like GLP-1. However, in T2DM, the mechanism focuses on reversing chronic insulin resistance and preserving pancreatic β-cell function. In contrast, the role of fiber in GDM is uniquely characterized by its ability to modulate the pregnancy-specific inflammationnutrient barrier, potentially downregulating hepcidin to improve maternal micronutrient absorption and influence neonatal metabolic programming This is a narrative review the objective is to provide a comprehensive analysis of dietary fiber's role in diabetes management by (1) synthesizing the physiological and microbial mechanisms that distinguish or unify fiber's efficacy in T2DM and GDM; (2) evaluating clinical evidence regarding specific outcomes, such as HbA1c reduction and maternal insulin requirements; (3) discussing emerging innovations in designer prebiotics, functional fibers, and microbiome-responsive delivery systems; and (4) establishing a framework for precision nutrition to address interindividual variability and long-term remission in global diabetes care.

Despite extensive research on dietary fibers and glycaemic control, inconsistencies remain regarding optimal fibers types, doses, and individual responsiveness, particularly in gestational diabetes. Moreover, existing reviews rarely integrate gut microbiota-mediated mechanisms across both type 2 and gestational diabetes. Therefore, this review aims to critically synthesise mechanistic, clinical, and translational evidence on dietary fiber interventions in T2DM and GDM, with a focus on gut-derived pathways and clinical relevance.

Dietary Fiber: Classification and Clinical Utility

Although dietary fiber is traditionally classified as soluble or insoluble, this distinction alone is insufficient to explain metabolic outcomes in diabetes. Evidence suggests that viscosity, fermentability, and the capacity to modulate gut microbiota are more relevant determinants of glycaemic control. Viscous and fermentable fibers such as β-glucan, psyllium, and resistant starch are consistently associated with improved postprandial glucose regulation and insulin sensitivity. (Jones, 2014) [4] .

Soluble (Viscous) Fiber

Soluble fibers, such as β-glucan, pectin, and inulin, dissolve in water to form high-molecular-weight viscous gels.

Clinical Relevance: Soluble fiber is superior to insoluble fiber for acute glycemic control because its viscous nature physically slows gastric emptying and creates a luminal barrier that delays glucose absorption. This mechanism significantly blunts postprandial glucose excursions and reduces the immediate insulin demand on pancreatic β-cells.

Insoluble Fiber

Insoluble fibers, including cellulose and hemicellulose, remain intact throughout the gastrointestinal tract.

Clinical Relevance: While less effective at immediate glucose sequestration, insoluble fiber promotes metabolic health by accelerating intestinal transit and increasing stool bulk. Its primary role in diabetes management is the improvement of hepatic insulin sensitivity and long-term weight maintenance through enhanced satiety signals.

In the study area, the high energy requirement is believed to be one of the main reasons for natural resource degradation. In this region, winter lasts for five months (October to February) during which local people heat their homes throughout the day because of very low temperature. The present study was undertaken to investigate the availability of fuelwood, pattern of fuel wood collection and its impact on forest ecosystem.

Material and Methods

The present study was conducted in two villages namely village Chhani and Village Lanchaan of Chinta block of Bhaderwah forest situated between 32.98 North latitude to 75.71 East longitude of Bhaderwah forest division (J&K). The objective of the study was to collect the reliable data on fuel wood consumption of the area and also to evaluate the impact of fuel wood collection on forest ecosystem.

Resistant Starch (RS)

Resistant starch (found in cooked-cooled grains and green bananas) is metabolically distinct from other fibers because it functions as a high-efficiency prebiotic.

Clinical Relevance: Unlike viscous fibers that act through physical interference, RS is primarily a fermentative substrate. It is metabolically unique due to its high yield of butyrate, a short-chain fatty acid (SCFA) that directly strengthens gut barrier integrity and activates G-protein coupled receptors to enhance systemic insulin sensitivity.

Functional and Novel Fiber Sources

Functional fibers are isolated or synthetic carbohydratessuch as psyllium, resistant dextrins, and polydextrose engineered for specific physiological endpoints.

Clinical Utility: Emerging sustainable sources, including algal alginates and insect-derived chitin, offer potent prebiotic effects that support gut microbiota diversity. Notably, psyllium husk is clinically recognized for its dual capacity to lower LDL cholesterol and stabilize blood glucose in T2DM patients by forming robust viscous gels (Slavin, 2021) [4] . Dietary fibers are broadly categorized based on their solubility, fermentability, and physiological function. The primary categories include: [4] and updated with recent findings (Zhu et al., 2021) [5] .

Sources of Dietary Fiber

Dietary fiber can be obtained from a variety of plant-based, algal, and animal/insect-based sources. In recent years, underutilized agricultural by-products have gained attention as sustainable fiber-rich ingredients for functional foods. Recent research highlights psyllium husk as one of the most clinically effective soluble fibers for glycemic and lipid control in T2DM (Asano et al., 2022) [1] . Similarly, agroindustrial residues such as pumpkin pulp and prickly pear husk have demonstrated promising techno-functional properties in bakery and beverage applications, offering both nutritional and sustainability benefits (Martínez-Villaluenga & Peñas, 2020) [3] .

Mechanistic Pathways Linking Dietary Fiber to Glycemic Regulation

Dietary fiber serves as a foundational element of Medical Nutrition Therapy (MNT), exerting antidiabetic effects through a multi-layered cascade of physiological, biochemical, and microbial pathways. These mechanisms are broadly categorized into colonic fermentation-driven signaling and upper-gastrointestinal physical interference.

The SCFA Incretin GPR Axis: A Unified Signalling Pathway

A major metabolic impact of fiber is mediated by the production of Short-Chain Fatty Acids (SCFAs)-primarily acetate, propionate, and butyrate during colonic fermentation. This process acts as a systemic signaling hub that links the gut microbiome to host glucose homeostasis.

• SCFA Production and Gut Barrier Integrity:

Beneficial taxa such as Bifidobacterium, Akkermansia muciniphila, and Faecalibacterium prausnitzii ferment prebiotic fibers to generate SCFAs. Butyrate serves as the primary energetic substrate for colonocytes and upregulates tight-junction proteins, thereby reducing intestinal permeability. This prevents the translocation of pro-inflammatory endotoxins (LPS), mitigating the systemic inflammation that drives insulin resistance (Qin et al., 2022) [12] .

• G-Protein Coupled Receptor (GPR) Activation:

SCFAs act as ligands for GPR41 (FFAR3) and GPR43 (FFAR2) located on enteroendocrine L-cells. As described in this integrated signaling model, activation of these receptors triggers the secretion of: • Glucagon-like peptide-1 (GLP-1): Enhances glucosedependent insulin secretion, suppresses glucagon, and preserves pancreatic β-cell function.

• Peptide YY (PYY): Modulates hypothalamic appetite centers to promote satiety and reduce caloric intake. • Systemic Metabolic Effects: Beyond the gut, propionate modulates hepatic gluconeogenesis and increases satiety, while acetate acts as a substrate for peripheral tissues, collectively reducing visceral adiposity and improving HOMA-IR scores (Canfora & Blaak, 2020) [11] .

Physical Modulation of Nutrient Kinetics

While the SCFA axis provides long-term metabolic programming, the physical properties of fiber provide immediate postprandial benefits:

• Viscosity and Gastric Emptying: Viscous soluble fibers (e.g., β-glucan, psyllium) form intraluminal gellike matrices. This physical barrier slows gastric emptying and sterically hinders the access of digestive enzymes to carbohydrates. • Absorption Attenuation: By slowing the rate of glucose diffusion across the intestinal epithelium, these fibers reduce postprandial glucose excursions by up to 30%. This "flattening" of the glucose curve minimizes the immediate demand for insulin, a critical factor in managing both T2DM and GDM (Zhang et al., 2022) [15] . [17] .

Key features

• Precision targeting of microbial strains (e.g.,

Bifidobacterium adolescentis, Akkermansia muciniphila).

• Enhanced stability and resistance to premature fermentation.

• Potential for personalization based on gut microbiome profiling.

Functional Fibers

Definition: Isolated, purified, or synthesized non-digestible carbohydrates that provide documented physiological benefits beyond laxation (Slavin, 2021) [4] . Examples:

Synbiotic Pairing

The combination of designer prebiotics with next-generation probiotics is termed designer synbiotics it is emerging as a promising strategy in metabolic health. By pairing specific probiotic strains with their optimal fiber substrate, researchers aim to maximize colonization success and metabolic output (Carding et al., 2023) [16] .

Example pairings

Akkermansia muciniphila combined with arabinoxylan enhances mucin layer integrity and promotes metabolic flexibility through improved gut barrier function and anti-inflammatory effects. • Bifidobacterium adolescentis fermentation of fructooligosaccharides (FOS) boosts acetate and butyrate production, facilitating beneficial cross-feeding interactions that support gut health and insulin sensitivity.

Furthermore, designer synbiotics are emerging as a strategy to mitigate the adverse effects of concurrent micronutrient interventions. Iron fortification, often required in diabetic populations due to restricted diets, can inadvertently increase fecal pathogens and gut inflammation in environments with poor hygiene. However, recent trials indicate that pairing iron with prebiotic galactooligosaccharides (GOS) significantly mitigates these adverse effects on the gut microbiome while maintaining iron efficacy. This suggests that functional fibers can serve a dual purpose: improving metabolic control and protecting the gut ecosystem against the side effects of mineral supplementation.

Microbiome Responsive Delivery Systems

Recent fiber formulations employ smart delivery systems that release prebiotics only in the targeted section of the gut:

• pH-sensitive hydrogels: Dissolve at colonic pH (~7), reducing premature fermentation.

• Enzyme-responsive nanoparticles: Trigger release in the presence of microbial β-galactosidase. • Mucoadhesive coatings: Extend gut retention time for increased fermentation.

Such systems can improve tolerance in sensitive individuals (e.g., IBS patients) and enhance efficacy in glucose regulation (Shin et al., 2024) [18] .

Future Perspectives

The integration of AI-driven microbiome analysis with personalized fiber formulations could transform diabetes management. Companies are now piloting algorithms that recommend custom fiber blends based on stool microbiome sequencing, dietary habits, and metabolic profiles (Wilson et al., 2025) [33] . However, regulatory frameworks for these products remain under development, and long-term clinical safety data are still limited.

Dietary Fiber in Gestational Diabetes Mellitus (GDM)

Gestational Diabetes Mellitus (GDM) is a transient yet highrisk metabolic state characterized by glucose intolerance with onset during the second or third trimester. Unlike T2DM, GDM pathophysiology is driven by placental hormones such as human placental lactogen (hPL), cortisol, and progesterone which induce a state of physiological insulin resistance to ensure adequate nutrient supply to the fetus. When maternal β-cell compensation fails to meet this demand, GDM occurs.

Pregnancy-Specific Mechanistic Pathways

Dietary fiber acts through unique physiological channels in the pregnant state:

• Mitigation of Placenta-Induced Insulin Resistance:

While placental hormones naturally drive resistance, fiber-derived SCFAs (as detailed in Section 3) offer a counter-regulatory mechanism by enhancing peripheral insulin sensitivity, thereby narrowing the "insulin gap" created by the placenta.

• The "Inflammation-Nutrient Barrier" and Hepcidin Regulation: Pregnancy in the context of GDM and obesity often triggers chronic low-grade inflammation, which upregulates hepcidin. Hepcidin blocks maternal iron absorption, leading to functional iron deficiency. High-fiber diets modulate the gut-microbiota axis to suppress systemic pro-inflammatory cytokines, potentially downregulating hepcidin and restoring essential micronutrient flux to the fetus.

• Maternal-Fetal Microbiome Transfer: Emerging evidence suggests that maternal fiber intake shapes the maternal gut microbiome, which may influence the initial microbial seeding of the neonate. By fostering a "eubiotic" maternal environment rich in Bifidobacterium, fiber interventions may program neonatal metabolic health even before birth.

Stratification of Clinical Outcomes

To evaluate the clinical efficacy of fiber in GDM, outcomes must be bifurcated into maternal and fetal compartments: [24] High-fiber diet (≥28 g/day) in GDM patients 8 weeks Significant reduction in fasting plasma glucose, decreased HbA1c, and improved lipid profile. Jovanovic et al, 2023 [21] Psyllium husk supplementation (10 g/day)

Clinical Evidence Supporting Fiber Intake in GDM

6 weeks Reduced postprandial glucose levels and lowered daily insulin requirements.

Hasain et al., 2021 [20] Inulin-enriched diet (10 g/day) 12 weeks Increased relative abundance of Bifidobacterium spp., accompanied by decreased inflammatory markers. Rasmussen et al., 2021 [23] Resistant starch 8 weeks Enhanced insulin sensitivity and reduced circulating pro-inflammatory cytokines.

Clinical Evidence and Meta-Analyses in Type 2 Diabetes Mellitus (T2DM)

A substantial body of evidence supports the role of dietary fiber in improving glycemic control, lipid metabolism, and inflammatory markers in T2DM. Multiple randomized controlled trials (RCTs) and meta-analyses confirm that both soluble and insoluble fibers exert beneficial effects, with viscous soluble fibers producing the most consistent glycemic improvements (Reynolds et al., 2020; McRae, 2022) [9,27] . McRae, 2022 [27] Psyllium supplementation (10-15 g/day) 8 weeks Lowered HbA1c, improved lipid profile, and reduced systolic blood pressure.

Summary of Major Clinical Trials

Sun et al., 2023 [24] High-fiber, plant-based diet 24 weeks Achieved 37% T2DM remission rate (HbA1c < 6.5% without medication).

Mah et al., 2024

GOS-enriched functional beverage 10 weeks Increased Bifidobacterium abundance, reduced HbA1c, and improved gut barrier function.

Practical Recommendations for Dietary Fiber Intake in Diabetes Management:

Optimizing dietary fiber intake is a cornerstone of Medical Nutrition Therapy (MNT) for individuals with type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM), and those at high risk of developing diabetes. Clinical guidelines emphasize a gradual increase in fiber consumption to target levels that improve glycemic control, promote satiety, and support cardiovascular health, while minimizing gastrointestinal discomfort (Evert et al., 2022; ADA, 2023) 31[] .

Recommendations by Life Stage and Health Status

Research Gaps and Future Directions

Despite strong evidence supporting the role of dietary fiber in diabetes prevention and management, several gaps remain in understanding optimal fiber type, dose, personalization, and long-term outcomes. Addressing these gaps will enhance the clinical utility of fiber-based interventions.

Variability in Glycemic Response Current Challenge

Interindividual variability in glycemic improvement following dietary fiber intake is influenced by genetic predispositions, baseline gut microbiota composition, and distinct metabolic phenotypes, as evidenced by recent studies (Zeevi et al., 2022) 34[] .

Future Direction

Leveraging gut microbiome sequencing integrated with personalized nutrition algorithms holds promise for tailoring fiber interventions to individual metabolic profiles, thereby maximizing glycemic control efficacy.

Underrepresentation of Diverse Populations Current Challenge

Most clinical trials investigating dietary fiber effects have been conducted in high-income countries, with a notable paucity of data from low-and middle-income regions where diabetes incidence is rapidly rising (Hawkins et al., 2023) [32] .

Future Direction

Designing culturally appropriate, locally sourced high-fiber dietary interventions is critical for ensuring accessibility, affordability, and long-term sustainability in these populations.

Lack of Long-Term Clinical Trials Current Challenge

Most existing studies on dietary fiber interventions have durations ranging from 4 to 12 weeks, potentially insufficient to capture sustained metabolic, cardiovascular, and diabetic remission outcomes (McRae, 2022) [27] .

Future Direction

There is a pressing need for multi-year randomized controlled trials that evaluate the long-term effects of fiber intake on diabetes remission, complication rates, and mortality.

Limited Data on Gestational Diabetes Mellitus (GDM) Current Challenge

Although dietary fiber has demonstrated benefits in GDM management, few randomized controlled trials have exclusively focused on this condition, and mechanistic insights into maternal-fetal microbiome transfer remain limited (Hasain et al., 2021) [20] .

Future Direction

Expanding research efforts to investigate the impact of fiber-induced microbiota modulation on neonatal metabolic programming is warranted to improve maternal and offspring health outcomes.

Integration of Functional and Designer Fibers Current Challenge

While designer prebiotics and microbiome-responsive delivery systems show potential, robust large-scale validation in diabetic cohorts is still lacking (Singh et al., 2023) [19] .

Future Direction

Clinical trials combining precision-engineered prebiotics with next-generation probiotics (designer synbiotics) are essential to assess their synergistic effects on insulin sensitivity and systemic inflammation.

Technological Innovations

• AI-Powered Personalization: Advanced artificial intelligence platforms can integrate continuous glucose monitoring (CGM) data with microbiome profiles to predict and recommend optimal fiber types for personalized metabolic benefit (Wilson et al., 2025) [33] . • Food Fortification Strategies: Incorporation of fiberrich agro-industrial byproducts, such as pumpkin pulp and prickly pear husk, into staple foods can enhance population-wide fiber intake while supporting environmental sustainability.

Conclusion

Dietary fiber is far more than a simple digestive aid; it is a multifunctional nutritional component with substantial implications for the prevention and management of diabetes mellitus. Evidence from mechanistic studies, randomized controlled trials, and meta-analyses consistently demonstrates that both soluble and insoluble fibers contribute to improved glycemic control, enhanced insulin sensitivity, favorable modulation of gut microbiota, stimulation of incretin secretion, and support for weight management. In Type 2 Diabetes Mellitus (T2DM), high-fiber dietary patterns particularly those enriched with viscous soluble fibers such as β-glucan, psyllium, and inulin are associated with clinically meaningful reductions in HbA1c, attenuation of postprandial glycemic excursions, and improvements in lipid profiles. In Gestational Diabetes Mellitus (GDM), dietary fiber offers dual benefits: optimizing maternal metabolic regulation and potentially influencing fetal metabolic programming via microbiota modulation, while reducing the risk of pregnancy-related complications. The advent of designer prebiotics, functional fibers, and microbiome-responsive delivery systems marks a new frontier in precision nutrition, enabling individualized fiber interventions aligned with specific microbiome signatures and metabolic phenotypes. Nonetheless, critical research gaps such as interindividual variability in metabolic response, the scarcity of long-term outcome studies, and the underrepresentation of diverse populations must be addressed before these innovations can be mainstreamed in clinical practice. From a public health perspective, promoting dietary fiber intake represents a low-cost, accessible, and sustainable strategy with broad cardiometabolic benefits. Realizing this potential will require coordinated action among researchers, clinicians, policymakers, and the food industry to embed fiber-rich diets and fortified functional foods as a core element of diabetes prevention and management strategies worldwide.

In conclusion, dietary fiber should not be regarded as a peripheral supplement in diabetes care, but as a foundational therapeutic asset bridging gut health and glucose regulation, and offering an integrative pathway toward improved outcomes and reduced global disease burden.

References

1. Asano I, Umemoto H, Watanabe S. Effect of psyllium on lipid and glucose metabolism, and gut microbiota in patients with type 2 diabetes mellitus. Nutrients. 2022;14(4):800.
2. Jones JM. CODEX-aligned dietary fiber definitions help to bridge the 'fiber gap'. Nutr J. 2014;13(1):34.
3. Martínez-Villaluenga C, Peñas E. Technological and nutritional aspects of underutilized legumes: The case of Vicia faba L. Trends Food Sci Technol. 2020;99:5869.
4. Slavin JL. Dietary fiber and body weight. Nutrition. 2021;84:111102.
5. Zhu Y, Wang Y, Wang Y, Yuan C. Advances in dietary fiber characterization and its effects on metabolic health. Crit Rev Food Sci Nutr. 2021;61(17):28332851.
6. Guasch-Ferré M, Li J, Hu FB, Salas-Salvadó J. Dietary fiber and metabolic health: Advances in epidemiologic, clinical, and mechanistic research. Nat Rev Endocrinol. 2022;18(7):479-493.
7. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: IDF; 2023.
8. McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P. Gestational diabetes mellitus. Nat Rev Dis Primers. 2022;8(1):63.
9. Saeedi P, Karuranga S, Hammond A, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045. Diabetes Res Clin Pract. 2023;185:109687.
10. Canfora EE, Blaak EE. The role of polyphenols and SCFAs in gut health and metabolic regulation. Curr Opin Clin Nutr Metab Care. 2020;23(6):478-485.
11. Qin Y, Roberts JD, Grimm ER, Li L. Modulation of the gut microbiota to improve type 2 diabetes. Nutrients. 2022;14(4):870.
12. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate GLP-1 secretion via FFAR2. Diabetes. 2021;70(6):1296-1309.
13. Weickert MO, Pfeiffer AFH. Impact of dietary fiber on insulin resistance. Gastroenterology. 2018;154(2):394409.
14. Zhang L, Xu Y, Wang H, et al. Effects of viscous dietary fiber on postprandial glycemia in type 2 diabetes. J Nutr. 2022;152(9):2078-2089.
15. Carding SR, Davis N, Hoyles L. The human intestinal microbiome in health and disease. Nat Rev Gastroenterol Hepatol. 2023;20(4):241-256.
16. Meynier A, Chanson-Rollé A, Lappi J. Functional fibers for metabolic health. Trends Food Sci Technol. 2022;120:88-102.
17. Shin H, Lee J, Park Y. Smart delivery systems for guttargeted prebiotics. J Funct Foods. 2024;108:105814.
18. Singh RK, Chang HW, Yan D, et al. Precision prebiotics for metabolic health. Nutrients. 2023;15(5):1102.
19. Hasain Z, Mokhtar NM, Kamaruddin NA, et al. Gut microbiota and gestational diabetes mellitus. Front Cell Infect Microbiol. 2021;11:760251.
20. Jovanovic M, Markovic T, Milovanovic J. Effects of psyllium supplementation in gestational diabetes mellitus. Eur J Clin Nutr. 2023;77(4):597-605.
21. Pheiffer C, Dias S, Rheeder P, Adam S. Antiinflammatory effects of dietary fibre in gestational diabetes. Nutrients. 2021;13(9):3224.
22. Rasmussen L, Christensen M, Madsen ML. Resistant starch improves insulin sensitivity in gestational diabetes. Clin Nutr. 2021;40(10):5408-5416.
23. Sun Y, Liu J, Li X. High dietary fiber intake improves glycemic control in gestational diabetes. Diabetes Ther. 2023;14(3):761-774.
24. Chen C, Zeng Y, Xu J, et al. Effects of oat β-glucan on glycemic control in type 2 diabetes. J Funct Foods. 2021;77:104330.
25. Mah J, Choi S, Kim Y. Galactooligosaccharide beverage improves glycemic control. Nutrients. 2024;16(1):112.
26. McRae MP. Dietary fiber intake and glycemic control in type 2 diabetes mellitus. J Am Coll Nutr. 2022;41(1):42-52.
27. Wang Y, Harding SV, Thandapilly SJ, et al. Effects of inulin-type fructans on glycemic control. Eur J Clin Nutr. 2019;73(3):338-348.
28. Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Probiotic effects via butyrate-induced GLP-1 secretion. J Biol Chem. 2020;295(23):7831-7845.
29. American Diabetes Association. Standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S68S96.
30. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes. Diabetes Care. 2022;45(7):1578-1590.
31. Hawkins M, Sattar N, Zimmet P. Global perspectives on type 2 diabetes prevention. Lancet Diabetes Endocrinol. 2023;11(4):223-232.
32. Wilson BC, Vasquez LJ, Flint HJ. Personalized dietary fiber interventions for type 2 diabetes. Front Nutr. 2025;12:1456789.
33. Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2022;185(1):1-17.